Ertumaxomab
From Self-sufficiency
| Monoclonal antibody | |
|---|---|
| Type | Trifunctional antibody |
| Source | Template:Infobox drug/mab source |
| Target | HER2/neu, CD3 |
| Identifiers | |
| CAS Number | 509077-99-0 |
| ATC code | none |
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. As of September 2009[update], a Phase II clinical trial evaluating the treatment of breast cancer is recruiting participants.[1]
It is a so-called trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[2]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40x30px | This monoclonal antibody-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from September 2009
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- 2Fix
- Cancer treatments
- Pages with broken file links
- Monoclonal antibody stubs
